Published on : Apr 15, 2015
In a report published on Monday, April 13, 2015, Teva Pharmaceutical Industries’ stock had the ‘buy’ rating reiterated by the stock analysts at Deutsche Bank. At present, they have a US$70.00 as price objective on the stock, slightly up from their earlier price objective of US$68.00. The target price of Deutsche Bank would advocate a potential upside of around 6% from the firm’s existing price.
Teva Pharmaceutical Industries was trading up 0.06% during the mid-day trading on Monday. A total of 2,972,374 shares of the firm’s stock traded hands. It has a fifty-two week high of US$68.75 and a fifty-two week low of US$47.36. The stock has a US$60 50-day moving average of and a US$57 200-day moving average. The firm has a US$56.27 billion market cap and a P/E ratio of 18.56%.
Teva previously declared its quarterly return statistics on Thursday, February 5, 2015. The company recorded US$1.31 EPS for this quarter, meeting the consensus expectations of the analysts of US$1.31. The firm had generated revenue of US$5.17 billion for this quarter, comparing to the consensus expectations of US$5.17 billion. In between the same quarter the previous year, the firm posted US$1.42 EPS. The revenue garnered by Teva Pharmaceutical Industries has dropped to 4.8% comparing to the same quarter the previous year. On an average, analysts estimate that Teva will register US$5.15 EPS for the existing fiscal year.
The analysts at Barclays increased their target price on the shares of Teva from US$70 to US$75 and rated the enterprise as ‘overweight’ in a research publication on Tuesday, April 7, 2015.